Manufacturing News of Note—Colorcon creates VC fund; FDA standardizing assessments; Upperton adds tableting

stocks
(Pixabay)

> Pharma supplier Colorcon has created a $50 million venture capital fund to invest in what a spokesman says would be new manufacturing technologies like track-and-trace systems and artificial intelligence solutions but not in companies that develop APIs or molecules. Release

> The FDA is creating a new system it expects will provide the information about the inherent risk and control approaches for product design, manufacturing and facilities to improve its quality assessments. Story

> Australian CDMO Cell Therapies says it is the first company in Australia to be granted a product class (T cells) GMP manufacturing license by regulators for commercial supply of the cells. Release

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.

> U.K.-based clinical supply CDMO Upperton Pharma Solutions has invested in new tableting capabilities. Release

> French CMO Indicia Production has acquired Bio-Steril, also a French company, which specializes in the formulation and fill and finish of medical devices for medical and cosmetic uses. Release 

> GE Healthcare and the National Institute of Bioprocessing Research and Training in Dublin are working together to create training programs in biopharmaceutical and cell therapy development and manufacturing. Release

> CDMO Pharmaceutics International will manufacturer Sagent Pharmaceuticals' recently approved fulvestrant injection.  Release